IMMUNOHISTOCHEMISTRY, KI67

The IHC – Ki-67 test is an immunohistochemistry-based diagnostic assay used to detect Ki-67 protein expression in tissue samples. Ki-67 is a nuclear protein present in actively dividing cells and is considered one of the most important markers for measuring cell proliferation. Because cancer cells often grow and divide rapidly, Ki-67 helps pathologists evaluate how aggressively a tumor is behaving.

This test is widely used in oncology and pathology to assess the growth rate of various cancers. A higher Ki-67 index generally indicates a greater proportion of actively dividing tumor cells, which may suggest a more aggressive cancer. Conversely, a lower Ki-67 index often indicates slower tumor growth.

Ki-67 testing plays an important role in diagnosing, grading, and prognostic evaluation of many cancers, including breast cancer, lymphomas, neuroendocrine tumors, brain tumors, and soft tissue sarcomas.

Benefits of the Test

• Measures tumor cell proliferation activity
• Helps assess cancer aggressiveness
• Supports tumor grading and classification
• Assists in prognosis evaluation
• Helps guide treatment planning and monitoring

Why Doctors Recommend This Test

Doctors recommend the IHC Ki-67 test when evaluating benign and malignant tumors to determine their growth potential. It is commonly used in:

• Breast cancer evaluation
• Lymphoma classification
• Neuroendocrine tumor grading
• Brain tumor assessment
• Soft tissue sarcoma evaluation
• General oncology tumor profiling

Ki-67 is frequently used alongside other immunohistochemistry markers such as ER, PR, HER2, P53, Cyclin D1, CD markers, and neuroendocrine markers to provide a comprehensive tumor assessment.

Preparation Before Test

No special preparation is required for this test. Important considerations include:

• The test is performed on a biopsy or surgical tissue sample
• No fasting is required
• No medication restrictions are generally necessary
• Clinical history and imaging studies may support interpretation

Normal Reporting Time

The typical turnaround time is 3 to 5 working days, depending on tissue processing and laboratory workflow.

Who Should Take This Test

• Patients diagnosed with cancer
• Individuals undergoing tumor biopsy evaluation
• Patients requiring cancer grading and prognosis assessment
• Cases requiring treatment planning support
• Oncology patients undergoing immunohistochemistry profiling

The IHC Ki-67 test is an essential tool in modern cancer diagnostics. By measuring tumor proliferation activity, it helps clinicians understand tumor behavior, estimate prognosis, and make informed treatment decisions.

Clinical Significance

Ki-67 immunostaining is commonly used in the evaluation of:

• Breast carcinoma
• Non-Hodgkin lymphoma
• Neuroendocrine tumors
• Brain tumors
• Soft tissue sarcomas
• Prostate cancer
• Lung cancer
• Gastrointestinal malignancies

The percentage of Ki-67-positive tumor cells, often referred to as the Ki-67 Index, provides valuable information about tumor growth and biological behavior.